BenevolentAI: Combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. The unique computational R&D platform spans every step of the drug discovery process, powering a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and maintains successful collaborations including AstraZeneca, as well as leading research and charitable institutions. They are the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19.